嵌合抗原受体
生物
免疫疗法
基因工程
转基因生物
自身免疫
转基因
T细胞受体
T细胞
过继性细胞移植
细胞疗法
癌症免疫疗法
免疫学
计算生物学
癌症研究
免疫系统
细胞
遗传学
基因
作者
Gavin I. Ellis,Neil C. Sheppard,James L. Riley
标识
DOI:10.1038/s41576-021-00329-9
摘要
Genetically engineered T cell immunotherapies have provided remarkable clinical success to treat B cell acute lymphoblastic leukaemia by harnessing a patient's own T cells to kill cancer, and these approaches have the potential to provide therapeutic benefit for numerous other cancers, infectious diseases and autoimmunity. By introduction of either a transgenic T cell receptor or a chimeric antigen receptor, T cells can be programmed to target cancer cells. However, initial studies have made it clear that the field will need to implement more complex levels of genetic regulation of engineered T cells to ensure both safety and efficacy. Here, we review the principles by which our knowledge of genetics and genome engineering will drive the next generation of adoptive T cell therapies.
科研通智能强力驱动
Strongly Powered by AbleSci AI